<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on pharmaceutical products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- April 24 2025 Personnel Changes in Board Members and Corporate Officers of ASKA Pharmaceutical Holdings’ Subsidiaries
- April 24 2025 Change in Personnel and Member of Board of Directors’ Responsibilities of ASKA Pharmaceutical
- April 24 2025 Changes in Organizational, Personnel, and Member of Board of Directors’ Responsibilities of ASKA Pharmaceutical
- April 23 2025 ASKA Announces Phase III Clinical Trial Result of TRM-270
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings Co., Ltd.